ISO 18562-1:2017-03 (E)

Biocompatibility evaluation of breathing gas pathways in healthcare applications - Part 1: Evaluation a nd testing within a risk management process

Contents

Page

Foreword iv

Introduction v

1 Scope 1

2 Normative references 2

3 Termsanddefinitions 2

4 General principles applying to biocompatibility evaluation of medicaldevices 6
4.1 General 6
4.2 Type tests 7
4.3 Biocompatibility hazard identification 8
4.4 Extent of risk assessment 8
4.5 Biocompatibility evaluation plan 9
4.6 Selection of tests 10
4.7 Subsequent evaluation 10

5 Contamination of breathing gas from gaspathways 11
5.1 * Duration of use 11
5.2 Particulate matter (pm) emissions 13
5.3 Volatile organic compound (voc) emissions 13
5.4 Leachable substances in condensate 13

6 Adjustment for different patient groups 13
6.1 General considerations 13
6.2 Adjustment for body weight 13
6.3 * Deriving a permitted concentration from a tolerable exposure 14

7 * Deriving allowable limits 14
7.1 General process 14
7.2 For medical devices intended for limited exposure use (24 h) 15
7.3 For medical devices intended for prolonged exposure use (>24 h but <30 d) 16
7.4 For medical devices intended for permanent contact (30 d) 16

8 Riskbenefitanalysis 16

9 Assess the biocompatibility of the medicaldevice 17

Annex A (informative) Rationale and guidance 18

Annex B (informative) Reference to the essential principles 20

Annex C (informative)Terminology--Alphabetizedindexofdefinedterms 21

Bibliography 23